|
|
Efficacy of G-CSF-Priming in Elderly AML Patients
Basic Trial Information Trial Description Summary Eligibility Criteria Trial Contact Information
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
Over 60
|
|
|
|
Other
|
|
|
|
AML-elderly 01/99 Trial NCT00199147
|
|
|
Trial Description
Summary Aim of the study is to compare the efficacy of intensive induction therapy with Cytarabine, Idarubicin and Etoposide (IdAV) given in parallel with (G-CSF priming) and followed by G-CSF versus the same IdAV chemotherapy only followed by G-CSF (without priming) in elderly patients with de novo AML, secondary AML and advanced MDS. Moreover, the ability to mobilize sufficient numbers of peripheral blood stem cells (PBSC) for autologous PBSC transplantation after consolidation therapy with dose-reduced FLAG-Ida chemotherapy followed by G-CSF will be evaluated. Eligibility Criteria Inclusion Criteria: - Diagnosis of de-novo AML, FAB M0, 1, 2, 4-7 or
- Diagnosis of secondary AML after previous chemotherapy and/or radiation therapy or after preceeding MDS or
- Diagnosis of an advanced MDS, i.e. RAEB-t according to the FAB classification or
- Extramedullary AML (chloroma, “granulocytic sarcoma”)
- Age greater than 60 years (not including 60 years)
- ECOG performance status 0, 1, or 2
Exclusion Criteria: - Patients with a t(15;17) translocation
- Patients with severe cardiac disease (e.g. cardiac failure NYHA III/IV, myocardial infarction within the last 6 months; severe ventricular arrythmias (Lown III or IV)
- Patients with severe complications of the leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock.
- Severe pulmonary disease (diffusion capacity for CO2 of less than 50%)
- Significant renal dysfunction (creatinine clearance < 60/min/min)
- Bilirubin > 2mg% (>34.2 mmol/l)
- Patients with a clinically active second malignancy
- Patients with a psychiatric, addictive, or any disorder wich compromises ability to give truly informed consent for participating in this study
- Known refractoriness to platelet transfusion, inability to adequately substitute blood products
Trial Contact Information
Trial Lead Organizations/Sponsors Klinikum der J.W. Goethe Universitaet Oliver G Ottmann, MD | | Study Chair |
Trial Sites
|
|
|
|
Germany |
|
|
Frankfurt |
|
| | | | | | | Universitaetsfrauenklinik Frankfurt |
| | Oliver G Ottmann, MD |
Ph: ++49-69-6301-4802 |
|
Email:
ottmann@em.uni-frankfurt.de |
| | Gesine Bug, MD |
Ph: ++49-69-6301-4802 |
|
Email:
g.bug@em.uni-frankfurt.de |
| | Oliver G Ottmann, MD | Principal Investigator |
| | Gesine Bug, MD | Sub-Investigator |
|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00199147 Information obtained from ClinicalTrials.gov on September 15, 2008 Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov. Back to Top |
|